tradingkey.logo
tradingkey.logo
Suchen

Guardant Health Inc

GH
Zur Watchlist hinzufügen
99.940USD
+3.230+3.34%
Handelsschluss 05/12, 16:00ETKurse um 15 Minuten verzögert
12.49BMarktkapitalisierung
VerlustKGV TTM

Guardant Health Inc

99.940
+3.230+3.34%

mehr Informationen über Guardant Health Inc Unternehmen

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Guardant Health Inc Informationen

BörsenkürzelGH
Name des UnternehmensGuardant Health Inc
IPO-datumOct 04, 2018
CEOTalasaz (Amirali)
Anzahl der mitarbeiter1999
WertpapierartOrdinary Share
GeschäftsjahresendeOct 04
Addresse3100 Hanover Street
StadtPALO ALTO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94304
Telefon18556988887
Websitehttps://guardanthealth.com/
BörsenkürzelGH
IPO-datumOct 04, 2018
CEOTalasaz (Amirali)

Führungskräfte von Guardant Health Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Helmy A. Eltoukhy, Ph.D.
Dr. Helmy A. Eltoukhy, Ph.D.
Chairperson of the Board, Co-Chief Executive Officer
Chairperson of the Board, Co-Chief Executive Officer
2.44M
+2.60%
Dr. Darya Chudova
Dr. Darya Chudova
Chief Technology Officer
Chief Technology Officer
79.91K
+73.68%
Dr. Craig Eagle, M.D.
Dr. Craig Eagle, M.D.
Chief Medical Officer
Chief Medical Officer
72.00K
+7.81%
Mr. John Gomes Saia
Mr. John Gomes Saia
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
65.95K
+13.72%
Mr. Kumud Kalia
Mr. Kumud Kalia
Chief Information Officer
Chief Information Officer
46.56K
+10.63%
Ms. Vijaya V. Gadde
Ms. Vijaya V. Gadde
Independent Director
Independent Director
24.31K
--
Ms. Myrtle Stephens Potter
Ms. Myrtle Stephens Potter
Independent Director
Independent Director
18.32K
--
Ms. Meghan V. Joyce
Ms. Meghan V. Joyce
Independent Director
Independent Director
11.18K
--
Mr. Musa Tariq
Mr. Musa Tariq
Independent Director
Independent Director
8.53K
+1.57%
Dr. Amirali Talasaz, Ph.D.
Dr. Amirali Talasaz, Ph.D.
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Helmy A. Eltoukhy, Ph.D.
Dr. Helmy A. Eltoukhy, Ph.D.
Chairperson of the Board, Co-Chief Executive Officer
Chairperson of the Board, Co-Chief Executive Officer
2.44M
+2.60%
Dr. Darya Chudova
Dr. Darya Chudova
Chief Technology Officer
Chief Technology Officer
79.91K
+73.68%
Dr. Craig Eagle, M.D.
Dr. Craig Eagle, M.D.
Chief Medical Officer
Chief Medical Officer
72.00K
+7.81%
Mr. John Gomes Saia
Mr. John Gomes Saia
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
65.95K
+13.72%
Mr. Kumud Kalia
Mr. Kumud Kalia
Chief Information Officer
Chief Information Officer
46.56K
+10.63%
Ms. Vijaya V. Gadde
Ms. Vijaya V. Gadde
Independent Director
Independent Director
24.31K
--

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Apr 6
Währung: USDAktualisiert: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Oncology
683.60M
69.61%
Biopharma and data
210.13M
21.40%
Screening
79.73M
8.12%
Licensing and other
8.56M
0.87%
Nach RegionUSD
Name
Umsatz
Anteil
United States
923.28M
94.02%
International
58.74M
5.98%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Oncology
683.60M
69.61%
Biopharma and data
210.13M
21.40%
Screening
79.73M
8.12%
Licensing and other
8.56M
0.87%

Aktionärsstatistik

Aktualisiert: Mon, May 11
Aktualisiert: Mon, May 11
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
6.51%
Vanguard Portfolio Management, LLC
4.40%
Vanguard Capital Management, LLC
4.24%
T. Rowe Price Associates, Inc.
4.15%
Invesco Advisers, Inc.
3.75%
Andere
76.94%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
6.51%
Vanguard Portfolio Management, LLC
4.40%
Vanguard Capital Management, LLC
4.24%
T. Rowe Price Associates, Inc.
4.15%
Invesco Advisers, Inc.
3.75%
Andere
76.94%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
47.17%
Investment Advisor/Hedge Fund
31.01%
Hedge Fund
14.16%
Individual Investor
4.08%
Research Firm
3.11%
Sovereign Wealth Fund
1.74%
Bank and Trust
1.09%
Pension Fund
0.83%
Private Equity
0.12%

Institutionelle Beteiligung

Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
894
134.76M
101.63%
-4.83M
2025Q4
825
125.59M
97.48%
-16.73M
2025Q3
765
128.93M
100.07%
-13.82M
2025Q2
759
134.16M
107.59%
-14.14M
2025Q1
783
130.34M
105.23%
-16.59M
2024Q4
746
130.16M
105.47%
-20.09M
2024Q3
780
137.29M
111.53%
-9.70M
2024Q2
801
127.50M
103.74%
-18.45M
2024Q1
826
124.00M
101.88%
-12.71M
2023Q4
856
120.18M
99.30%
-14.26M
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
8.63M
6.58%
+59.33K
+0.69%
Dec 31, 2025
T. Rowe Price Associates, Inc.
5.51M
4.2%
+1.41M
+34.38%
Dec 31, 2025
Invesco Advisers, Inc.
4.98M
3.79%
+333.09K
+7.17%
Dec 31, 2025
Two Sigma Investments, LP
4.55M
3.47%
+638.07K
+16.29%
Dec 31, 2025
Baillie Gifford & Co.
4.89M
3.73%
-237.67K
-4.63%
Dec 31, 2025
Capital International Investors
3.53M
2.69%
-1.16M
-24.75%
Dec 31, 2025
Geode Capital Management, L.L.C.
3.21M
2.45%
+277.00K
+9.43%
Dec 31, 2025
Franklin Advisers, Inc.
2.94M
2.24%
+23.45K
+0.80%
Dec 31, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Franklin Genomic Advancements ETF
9.3%
Global X Genomics & Biotechnology ETF
7.01%
ARK Genomic Revolution ETF
5.81%
First Trust Nasdaq Lux Digi Health Solutions ETF
5.17%
Invesco Dorsey Wright Healthcare Momentum ETF
4.73%
ROBO Global Healthcare Technology & Innovation ETF
3.53%
State Street SPDR S&P Health Care Services ETF
3.35%
iShares Health Innovation Active ETF
3.27%
Simplify Health Care ETF
2.36%
Alpha Architect U.S. Quantitative Momentum ETF
2.35%
Mehr Anzeigen
Franklin Genomic Advancements ETF
Anteil9.3%
Global X Genomics & Biotechnology ETF
Anteil7.01%
ARK Genomic Revolution ETF
Anteil5.81%
First Trust Nasdaq Lux Digi Health Solutions ETF
Anteil5.17%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil4.73%
ROBO Global Healthcare Technology & Innovation ETF
Anteil3.53%
State Street SPDR S&P Health Care Services ETF
Anteil3.35%
iShares Health Innovation Active ETF
Anteil3.27%
Simplify Health Care ETF
Anteil2.36%
Alpha Architect U.S. Quantitative Momentum ETF
Anteil2.35%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI